Skip to Content

Zirabev Approval History

FDA Approved: Yes (First approved June 27, 2019)
Brand name: Zirabev
Generic name: bevacizumab-bvzr
Dosage form: Injection
Company: Pfizer Inc.
Treatment for: Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer

Zirabev (bevacizumab-bvzr) is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer.

Zirabev (bevacizumab-bvzr) is the the second FDA-approved bevacizumab biosimilar, following the approval of Mvasi (bevacizumab-awwb) in September 2017.

Development History and FDA Approval Process for Zirabev

DateArticle
Jun 28, 2019Approval FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide